GynecologyGynecology2079-56962079-5831Consilium Medicum28275Research ArticleAtrophic vulvovaginitis: new trends in pharmacotherapyPrilepskayaV N-LedinaA Vantoninaledina@yandex.ru15122013156545609042020Copyright © 2013, Consilium Medicum2013The article presents the current data on the etiopathogenesis of atrophic vulvovaginitis, diagnostic criteria, clinical manifestations and modern drugs used to treat the pathological condition.atrophic vulvovaginitisurogenital atrophyestriolhormone replacement therapyOvipol Clioатрофический вульвовагинитурогенитальная атрофияэстриолзаместительная гормональная терапияОвипол Клио[Spinillo A, Bernuzzi A.M, Cevini C et al. The relationship of bacterial vaginosis, Candida and Trichomonas infection to symptomatic vaginitis in postmenopausal women attending a vaginitis clinic. Maturitas 1997; 27 (3): 253–60.][Балан В.Е. Принципы заместительной гормонотерапии урогенитальных расстройств. Гинекология. 2000; 2 (5): 140–2.][Сметник В.П. Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М.: МИА, 2001.][Nappi R.E, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233.][Bachmann G.A, Nevadunsky N.S. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61: 3090.][Kao A et al. Dyspareunia in postmenopausal women: a critical review. Pain Res. Manag 2008; 13 (3): 243–54.][Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt) 2009; 18 (10): 1595–606.][Beard M.K. Atrophic vaginitis. Can it be prevented as well as treated? Postgrad Med 1992; 91: 257.][Woods N.F, Mitchell E.S. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 (Suppl. 12B): 14.][Castelo-Branco C, Cancelo M.J, Villero J et al. Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 (Suppl. 1): S46.][Forsberg J.G. A morphologist approach to vagine - age - related changes and estrogen sensitivity. Maturitas 1995; 22: 7–15.][Назарова Н.М., Межевитинова Е.А. Урогенитальные нарушения в постменопаузе: опыт применения препарата «Овестин». Гинекология. 2006 (Экстравыпуск): 9–10.][Larson P.G, Platzs-Christiansen S.S. The vaginal pH and leucocyte epithelial cell ratio during normal menstrual cycle. Eur J Obstet Gyn Reprod Biol 1990; 38: 39–41.][Castelo-Branco C, Cancelo M.J, Villero J et al. Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 (Suppl. 1): S46.][Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008; 51 (3): 549–55.][Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. J Suckling. Cochrane Database Syst Rev 2006; 18 (4): CD001500.][Балан В.Е. Принципы заместительной гормонотерапии урогенитальных расстройств. Cons. Med. 2003; 5 (7): 413–7.][Костава М.Н., Прилепская В.Н., Быковская О.В. Шеечно - влагалищная экосистема в постменопаузе и заместительная гормонотерапия. Гинекология. 2006 (Экстравыпуск): 6–8.][Lee J.S, Ettinger B, Stanczyk F.Z et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3791.][Балан В.Е. Клиническая картина, диагностика и лечение вагинальной атрофии в климактерии. Гинекология. 2009; 2 (11):26–9.][The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007 (3 Pt. 1): 355–69.]